BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 30230534)

  • 21. Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment.
    Shen Y; Wu YC; Gu L
    Ann Transl Med; 2020 Nov; 8(21):1416. PubMed ID: 33313161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative Factors Associated with Extrathyroidal Extension in Papillary Thyroid Cancer.
    Kuo CY; Yang PS; Chien MN; Cheng SP
    Eur Thyroid J; 2020 Sep; 9(5):256-262. PubMed ID: 33088794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer.
    Li B; Geng R; Wu Q; Yang Q; Sun S; Zhu S; Xu Z; Sun S
    Front Oncol; 2020; 10():333. PubMed ID: 32226776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
    Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Yamamoto N; Ohe Y
    Cancer Immunol Immunother; 2020 Jul; 69(7):1229-1236. PubMed ID: 32152703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
    Verdura S; Cuyàs E; Cortada E; Brunet J; Lopez-Bonet E; Martin-Castillo B; Bosch-Barrera J; Encinar JA; Menendez JA
    Aging (Albany NY); 2020 Jan; 12(1):8-34. PubMed ID: 31901900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
    Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
    Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-cancer analysis reveals molecular patterns associated with age.
    Shah Y; Verma A; Marderstein AR; White J; Bhinder B; Garcia Medina JS; Elemento O
    Cell Rep; 2021 Dec; 37(10):110100. PubMed ID: 34879281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints.
    Wu Y; Wei J; Chen X; Qin Y; Mao R; Song J; Fan Y
    Int J Cancer; 2019 Apr; 144(7):1657-1663. PubMed ID: 30230534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of immunity in elderly cancer.
    Malaguarnera L; Cristaldi E; Malaguarnera M
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):40-60. PubMed ID: 19577481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.